Switch theme
Sign up to access all valuation multiples
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
2015
108
LTM Revenue n/a
LTM EBITDA -$183M
$370M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pharvaris has a last 12-month revenue of n/a and a last 12-month EBITDA of -$183M.
In the most recent fiscal year, Pharvaris achieved revenue of n/a and an EBITDA of -$145M.
Pharvaris expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharvaris valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$96.7M | -$145M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$76.3M | -$101M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pharvaris's stock price is $13.
Pharvaris has current market cap of $688M, and EV of $370M.
See Pharvaris trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $370M | $688M | XXX | XXX | XXX | XXX | $-3.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pharvaris has market cap of $688M and EV of $370M.
Pharvaris's trades at n/a LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate Pharvaris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pharvaris and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $370M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.5x | XXX | XXX | XXX |
| P/E | -5.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharvaris's NTM/LTM revenue growth is Infinity%
Pharvaris's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Pharvaris's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pharvaris's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pharvaris and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 50% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharvaris acquired XXX companies to date.
Last acquisition by Pharvaris was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharvaris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pharvaris founded? | Pharvaris was founded in 2015. |
| Where is Pharvaris headquartered? | Pharvaris is headquartered in United States of America. |
| How many employees does Pharvaris have? | As of today, Pharvaris has 108 employees. |
| Who is the CEO of Pharvaris? | Pharvaris's CEO is Mr. Berndt Modig. |
| Is Pharvaris publicy listed? | Yes, Pharvaris is a public company listed on NAS. |
| What is the stock symbol of Pharvaris? | Pharvaris trades under PHVS ticker. |
| When did Pharvaris go public? | Pharvaris went public in 2021. |
| Who are competitors of Pharvaris? | Similar companies to Pharvaris include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pharvaris? | Pharvaris's current market cap is $688M |
| What is the current EBITDA of Pharvaris? | Pharvaris's last 12-month EBITDA is -$183M. |
| What is the current EV/EBITDA multiple of Pharvaris? | Current EBITDA multiple of Pharvaris is -2.2x. |
| Is Pharvaris profitable? | Yes, Pharvaris is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
